Compare NXTS & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXTS | JAGX |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | Israel | United States |
| Employees | 9 | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 5.0M |
| IPO Year | N/A | 2014 |
| Metric | NXTS | JAGX |
|---|---|---|
| Price | $4.63 | $3.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 19.7K | ★ 428.3K |
| Earning Date | 05-16-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,511,000.00 |
| Revenue This Year | N/A | $61.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.55 | $0.22 |
| 52 Week High | $6.21 | $8.11 |
| Indicator | NXTS | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 61.39 | 60.44 |
| Support Level | $3.92 | $1.12 |
| Resistance Level | $5.31 | $8.00 |
| Average True Range (ATR) | 0.62 | 0.60 |
| MACD | -0.08 | 0.13 |
| Stochastic Oscillator | 42.82 | 41.14 |
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.